429 related articles for article (PubMed ID: 32574517)
21. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis. A Nationwide Cohort Study.
Moon SW; Kim SY; Chung MP; Yoo H; Jeong SH; Kim DS; Song JW; Lee HL; Choi SM; Kim YW; Kim YH; Park CS; Park SW; Park JS; Jegal Y; Lee J; Uh ST; Kim TH; Lee JH; Kim YH; Shin B; Lee HK; Yang SH; Lee H; Kim SH; Lee EJ; Choi HS; Shin H; Park YB; Shin JW; Park MS
Ann Am Thorac Soc; 2021 May; 18(5):780-787. PubMed ID: 33270528
[No Abstract] [Full Text] [Related]
23. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
Poletti V; Vancheri C; Albera C; Harari S; Pesci A; Metella RR; Campolo B; Crespi G; Rizzoli S;
Respir Res; 2021 Feb; 22(1):66. PubMed ID: 33627105
[TBL] [Abstract][Full Text] [Related]
24. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry.
Fernández-Fabrellas E; Molina-Molina M; Soriano JB; Portal JAR; Ancochea J; Valenzuela C; Xaubet A;
Respir Res; 2019 Jun; 20(1):127. PubMed ID: 31208406
[TBL] [Abstract][Full Text] [Related]
25. Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis.
LaCamera PP; Limb SL; Haselkorn T; Morgenthien EA; Stauffer JL; Wencel ML
Chron Respir Dis; 2019; 16():1479973119879678. PubMed ID: 31558049
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry.
Kim HJ; Snyder LD; Neely ML; Hellkamp AS; Hotchkin DL; Morrison LD; Bender S; Leonard TB; Culver DA;
Lung; 2022 Feb; 200(1):21-29. PubMed ID: 34997268
[TBL] [Abstract][Full Text] [Related]
27. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
[TBL] [Abstract][Full Text] [Related]
28. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
30. Anxiety and depression status in patients with idiopathic pulmonary fibrosis and outcomes of nintedanib treatment: an observational study.
He X; Ji J; Pei Z; Luo Z; Fang S; Liu X; Lei Y; Yan H; Guo L
Ann Med; 2024 Dec; 56(1):2323097. PubMed ID: 38581666
[TBL] [Abstract][Full Text] [Related]
31. High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study.
Ryerson CJ; Camp PG; Eves ND; Schaeffer M; Syed N; Dhillon S; Jensen D; Maltais F; O'Donnell DE; Raghavan N; Roman M; Stickland MK; Assayag D; Bourbeau J; Dion G; Fell CD; Hambly N; Johannson KA; Kalluri M; Khalil N; Kolb M; Manganas H; Morán-Mendoza O; Provencher S; Ramesh W; Rolf JD; Wilcox PG; Guenette JA
Ann Am Thorac Soc; 2016 Sep; 13(9):1640-7. PubMed ID: 27348402
[TBL] [Abstract][Full Text] [Related]
32. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.
Kreuter M; Swigris J; Pittrow D; Geier S; Klotsche J; Prasse A; Wirtz H; Koschel D; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Held M; Bahmer T; Oqueka T; Frankenberger M; Behr J
Respir Res; 2019 Mar; 20(1):59. PubMed ID: 30876420
[TBL] [Abstract][Full Text] [Related]
33. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
Khor YH; Goh NSL; Wong AW; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
Ann Am Thorac Soc; 2022 Jun; 19(6):962-970. PubMed ID: 35007498
[No Abstract] [Full Text] [Related]
34. Real-life data in the treatment and follow-up of idiopathic pulmonary fibrosis: A single-center study.
Üzer F; Akanlar S; Çilli A
Tuberk Toraks; 2023 Dec; 71(4):347-355. PubMed ID: 38152005
[TBL] [Abstract][Full Text] [Related]
35. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
36. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Kirchgaessler KU; Bartley K; Bondue B
BMJ Open Respir Res; 2018; 5(1):e000331. PubMed ID: 30555708
[TBL] [Abstract][Full Text] [Related]
37. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
38. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ
Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry.
Jegal Y; Park JS; Kim SY; Yoo H; Jeong SH; Song JW; Lee JH; Lee HL; Choi SM; Kim YW; Kim YH; Choi HS; Lee J; Uh ST; Kim TH; Kim SH; Lee WY; Kim YH; Lee HK; Lee EJ; Heo EY; Yang SH; Kang HK; Chung MP;
Tuberc Respir Dis (Seoul); 2022 Apr; 85(2):185-194. PubMed ID: 34902237
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
